Eberlein T J, Schoof D D, Jung S E, Davidson D, Gramolini B, McGrath K, Massaro A, Wilson R E
Department of Surgery, Brigham & Women's Hospital, Boston, MA 02115.
Arch Intern Med. 1988 Dec;148(12):2571-6.
Adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer (LAK) cells has proved to be successful in the treatment of some patients with metastatic cancer, but not without a significant degree of associated toxic effects. The primary goal of this study was to substantially reduce the toxicity of this complex and expensive treatment, while maintaining or improving efficacy. To this end, 29 patients were treated with LAK cells in conjunction with a low-dose regimen of interleukin 2 and a prolonged period of administration following LAK cell infusion. This protocol resulted in a considerable reduction in toxicity, as compared with that described in previous studies, without compromising the efficacy. This study offers further confirmation that adoptive immunotherapy of metastatic cancer can be clinically beneficial to patients for whom no other effective therapy is presently available.
高剂量白细胞介素2和淋巴因子激活的杀伤细胞（LAK细胞）的过继性免疫疗法已被证明在治疗一些转移性癌症患者方面是成功的，但并非没有显著程度的相关毒性作用。本研究的主要目标是在维持或提高疗效的同时，大幅降低这种复杂且昂贵治疗的毒性。为此，29例患者接受了LAK细胞治疗，并结合低剂量白细胞介素2方案以及LAK细胞输注后的延长给药期。与先前研究中描述的情况相比，该方案导致毒性显著降低，且不影响疗效。这项研究进一步证实，转移性癌症的过继性免疫疗法对于目前没有其他有效治疗方法的患者在临床上可能有益。
